Evaluación del consumo de antibióticos en la Unidad de Cuidados Intensivos desde 2016 a 2020 en un hospital de segundo nivel

  1. Tania González Furelos 1
  2. Iria Rodríguez Legazpi 1
  3. Eva Fraga Bueno 1
  4. Isaura Rodríguez Penín 1
  1. 1 Complexo Hospitalario Universitario de Ferrol
    info

    Complexo Hospitalario Universitario de Ferrol

    Ferrol, España

Revista:
Pharmaceutical care España

ISSN: 1139-6202

Ano de publicación: 2022

Volume: 24

Número: 5

Páxinas: 27-38

Tipo: Artigo

Outras publicacións en: Pharmaceutical care España

Resumo

Objective: Monitoring the consumption of anti-microbials in hospitals is a necessary measure to evaluate the rational use of these drugs. The main indicator to carry out this monitoring and to know the pressure or exposure of antimicrobials at the hospital level is the defined daily dose (DDD) for every 100 stays and day (s-d). The main objective is to analyze the evolution of the use of antibiotics in an Intensive Care Unit (ICU) of a second level hospital over 5 years. Methods: It was carried out an observational, retrospective study that analyzes the consumption of antibiotics in the ICU, making a comparison with the global data of the hospital, using DDD/100 s-d as the unit of measurement.Results: 28 drugs were included, corresponding to 25 active ingredients. The mean global hospital consumption was 67.98; rising to 89.17 in the ICU. There was a trend towards reductions in consump-tion until 2020, when antibiotics such as azithromy-cin or ceftriaxone stand out. In the ICU, the most consumed drugs in 2016 were meropenem and amoxicillin/clavulanate, followed by ciprofloxacin and piperacillin/tazobactam. However, in 2020, meropenem and amoxicillin/clavulanate, in spite of showing lower values, continued to be the most used ones, while ciprofloxacin became one of the least used.Conclusions: The analysis of DDD/100 s-d in the ICU is a useful tool to monitor the consumption of antimicrobials and see consumption trends, which will allow the implementation of measures that promote the rational and safe use of these drugs

Referencias bibliográficas

  • Antibiotic resistance [Internet]. [cited February 9, 2022]. Available at: https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance
  • Hermosilla Nájera L, Canut Blasco A, Ulibarrena Sanz M, Abásolo Osinaga E, Abecia Inchaurregui L.C. Evolución de la utilización de antimicrobianos durante los años 1996-2000 en un hospital general. Estudio pormenorizado de la UCI. Farm Hosp. 2003, 27(1):31-37. Available at: https://www.elsevier.es/es-revista-farmacia-hospitalaria-121-articulo-evolucion-utilizacion-antimicrobianos-durante-anos-13118736
  • Collado R, Losa JE, Álvaro EAq, Toro P, Moreno L, Pérez M. Evaluación del consumo de antimicrobianos mediante DDD/100 estancias versus DDD/100 altas en la implantación de un Programa de Optimización del Uso de Antimicrobianos. Revista Española de Quimioterapia. [Internet]. 2015; 28: 317-321. Available at: https://www.semanticscholar.org/paper/Evaluaci%C3%B3n-del-consumo-de-antimicrobianos-mediante-Collado-Losa/52fcf75f7d5ac9fe2114487268af7ae1725dfbaf
  • Rodríguez-Baño J, Paño-Pardo JR, Alvarez-Rocha L, Asensio A, Calbo E, Cercenado E, et al. Programs for optimizing the use of antibiotics (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSPH consensus document. Enferm Infecc Microbiol Clin. January 2012;30(1):22.e1-22.e23. http://dx.doi.org/10.1016/j.eimc.2011.09.018
  • Kuster SP, Ruef C, Ledergerber B, Hintermann A, Deplazes C, Neuber L, et al. Quantitative antibiotic use in hospitals: comparison of measurements, literature review, and recommendations for a standard of reporting. Infection. December 2008;36(6):549–59. http://dx.doi.org/10.1007/s15010-008-7462-z
  • Aparaci Bolufer JV, Taboada Montero C. Estudio de la utilización de antibióticos de un hospital comarcal. Años 1998-2002. Farmacia Hospitalaria. 2004;28(6):410–8. Available at: https://www.elsevier.es/es-revista-farmacia-hospitalaria-121-pdf-13118709
  • WHOCC - ATC/DDD Index [Internet]. [cited January 26, 2022]. Available at: https://www.whocc.no/atc_ddd_index/
  • MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev. October 2005;18(4):638–56. http://dx.doi.org/10.1128/CMR.18.4.638-656.2005
  • Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. December 2, 2009;302(21):2323–9. http://dx.doi.org/10.1001/jama.2009.1754
  • Informe ENVIN-UCI 2020.pdf [Internet]. [cited March 14, 2022]. Available at: https://hws.vhebron.net/envin-helics/Help/Informe%20ENVIN-UCI%202020.pdf
  • Khan S, Hasan SS, Bond SE, Conway BR, Aldeyab MA. Antimicrobial consumption in patients with COVID-19: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2022;20(5):749-772. http://dx.doi.org/10.1080/14787210.2022.2011719
  • Olry de Labry-Lima A, Saez-de la Fuente J, Abdel-Kader Martin L, Alegre-del Rey EJ, García-Cabrera E, Sierra-Sánchez JF. Factores asociados a la mortalidad en pacientes hospitalizados por COVID-19 en España. Datos del Registro Español de Resultados de Farmacoterapia frente a COVID-19 (RERFAR). Farm Hosp. 2022;46(2):57-71. http://dx.doi.org/10.7399/fh.11714
  • Ul Mustafa Z, Salman M, Aldeyab M, Kow CS, Hasan SS. Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan. SN Compr Clin Med. 2021;3(8):1691–1695. http://dx.doi.org/10.1007/s42399-021-00966-5
  • Cantudo-Cuenca MR, Jimenez-Morales A, Martínez-de la Plata JE. Pharmacist-driven antimicrobial stewardship program in a long-term care facility by assessment of appropriateness. Sci Rep. 2021;11(1):18884. http://dx.doi.org/10.1038/s41598-021-98431-9 . Retraction in: Sci Rep. 2021;11(1):20580. http://dx.doi.org/10.1038/s41598-021-00221-w
  • Nakamura S, Arima T, Tashiro R, Yasumizu S, Aikou H, Watanabe E, et al. Impact of an antimicrobial stewardship in a 126-bed community hospital with close communication between pharmacists working on post-prescription audit, ward pharmacists, and the antimicrobial stewardship team. J Pharm Health Care Sci. 2021;7(1):25. http://dx.doi.org/doi:10.1186/s40780-021-00206-x